ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia... ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate.
- Mechanism
- Curator reviewed
ILY101 binds dietary phosphate in the gastrointestinal tract, facilitating excretion of phosphorus into feces. It is therefore anticipated to ameliorate hyperphosphatemia by reducing the absorption of dietary phosphate. Due to its low swelling rate after fluid absorption, less gastrointestinal adverse events, including constipation, flatulence and upper abdominal pain, are expected. Strong phosphorus binding capacity may result in the reduced number of tablets and improved compliance.
- Primary indication
- Investigated for use/treatment in kidney disease.Curator reviewed
- Code names
- ILY101
What you can answer from here — as of July 03, 2026
Which companies are running trials of ILY101, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account